Actuate gets $21.7M to expand clinical testing of lead candidate

With its $21.7 million series B round, Actuate plans to expand clinical testing of its GSK3B inhibitor into Europe and advance its pediatric neuroblastoma program for the candidate.

Kairos Ventures led the round, with participation by new investors DEFTA Partners and Tech Coast Angels and existing investor Bios Partners...